The effect of adenoid hypertrophy and adenoidectomy in patients on cardiovascular risk reduction.

In recent years, many studies have been published which state that there is a significant relationship between the increase in mean platelet volume (MPV) and the increase in cardiovascular disease risk.[2,3] Besides, other studies which investigated the relationship between adenoid hypertrophy, MPV, and cardiovascular disease risk have been reported.[4,5] Results of these studies reveal conflicting comments about the effect of MPV value on cardiovascular disease risk. Although a good number of assertive results have been announced in these studies, MPV value measurement has not been used sufficiently in the follow-up and treatment of patients clinically as there is no fully standardized method for the use of this parameter. Some of the factors that affect the standardization of MPV measurement are the environment of blood taking, type and amount of anticoagulant in the blood collection tube, the duration between blood taking and examination, the device used in examination, and the calibration time of the device.[3] It has been reported that there are measurement differences up to 40% among different devices used in the studies.[6,7] In this study, the fact that MPV value has been found higher in patients with adenoid hypertrophy in proportion to the control group is agreeable to the literature. However, we think that it is assertive to state that the decrease in MPV value measured in the third month in comparison with preoperative period in patients on whom adenoidectomy operation have been performed would enable cardiovascular risk reduction, and for that reason, MPV value may be a parameter for this situation. Since, as stated before, MPV value is a variable parameter, and if we think that the lifetime of thrombocytes is between seven and 10 days, this change in MPV expressed at the end of the study may arise from many other factors, as waiting for three months for control MPV can cause variance at hemogram parameters. While hemoglobin and thrombocyte count values between the control and patient groups were stated in the study, the values of preand postoperative patient groups and the changes in these values were not stated. Moreover, it is not clear how long blood samples taken from test subjects stayed in the tube with ethylenediamine tetraacetic acid and when the blood count was made. At the same time, the patients chosen for the study were well excluded in terms of cardiac disease, and it is difficult to say that cardiovascular disease risk will decrease at third month in this case group, which essentially has no cardiovascular disease risk.